Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of RZL-012 on Submental Fat Reduction

NCT04867434
Conditions
Submental Fat
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Submental Fat
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
Conditions
Submental Fat
Interventions
RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhattan, New York
Conditions
Submental Fat
Interventions
RZL-012
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Submental Fat
Interventions
RZL-012
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Manhattan, New York
Conditions
Lipedema, Dercum Disease
Interventions
RZL-012
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
20 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

NCT05445557
Conditions
Flank Mass
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

RZL-012 for Dercum's Disease Lipomas

NCT04229030
Conditions
Dercum's Disease Lipomas
Interventions
RZL-012, Vehicle
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Obesity, Weight Loss, Overweight and Obesity
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
West Bend, Wisconsin